Get the Stockscreener App
6.65
2.92%
-0.20
After Hours:
6.66
0.010
+0.15%
Novavax Inc stock is traded at $6.65, with a volume of 4.88M.
It is down -2.92% in the last 24 hours and up +5.56% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$6.85
Open:
$6.76
24h Volume:
4.88M
Relative Volume:
0.62
Market Cap:
$1.08B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-2.9039
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
-12.96%
1M Performance:
+5.56%
6M Performance:
-23.48%
1Y Performance:
-48.09%
1-Day Range:
$6.63
$6.90
1-Week Range:
$6.63
$7.69
52-Week Range:
$5.01
$15.22
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.65 | 1.11B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Is Novavax Inc. stock overvalued or undervaluedDaily Trading Forecasts From AI Tools - jammulinksnews.com
NVAX September 12th Options Begin Trading - Nasdaq
Novavax reports candidate vaccine against avian influenza - BioWorld MedTech
Novavax (NVAX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025 - Yahoo Finance
Novavax Inc. Reversal Rally May Surprise BearsMarket Momentum and Signal Alerts Suggest Reversal - metal.it
Novavax Inc. Recovery Hinges on Volume BreakoutTriple Return Setup With Risk Control Explained - metal.it
Novavax Inc. Company’s Quarterly Earnings Growth: What the Numbers SaySecure Capital Picks With Upside Potential Tracked - metal.it
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - MSN
What is the dividend policy of Novavax Inc. stockPhenomenal capital appreciation - jammulinksnews.com
When is Novavax Inc. stock expected to show significant growthDiscover stocks with superior performance - jammulinksnews.com
What are analysts’ price targets for Novavax Inc. in the next 12 monthsExplosive earnings growth - jammulinksnews.com
What is Novavax Inc. company’s growth strategyTake advantage of unprecedented market momentum - jammulinksnews.com
Novavax Inc. Earnings Report Breakdown: What Investors Should KnowCapital Safe Stock Watchlist - metal.it
How does Novavax Inc. generate profit in a changing economyBuild a portfolio that withstands market volatility - jammulinksnews.com
Why is Novavax Inc. stock attracting strong analyst attentionRapid market gains - jammulinksnews.com
Should I hold or sell Novavax Inc. stock in 2025Dynamic profit opportunities - jammulinksnews.com
What are the technical indicators suggesting about Novavax Inc.Unlock powerful portfolio optimization tools - jammulinksnews.com
Why Novavax Inc. stock attracts strong analyst attentionProfitable Yet Secure Picks - metal.it
What drives Novavax Inc. stock priceUnprecedented growth rates - PrintWeekIndia
What analysts say about Novavax Inc. stockAccelerated capital growth - Autocar Professional
Is Novavax Inc. a good long term investmentConsistently high returns - PrintWeekIndia
Here's Why Novavax (NVAX) is a Strong Momentum Stock - Yahoo.co
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued - Stocktwits
Novavax’s H5N1 vaccine shows promise with single-dose option - Investing.com India
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates - Benzinga
Novavax’s H5N1 vaccine shows promise with single-dose option By Investing.com - Investing.com South Africa
Novavax stock rises after promising H5N1 vaccine preclinical results By Investing.com - Investing.com Canada
Novavax (NVAX) Unveils Promising H5N1 Vaccine Candidate Data | N - GuruFocus
Breakthrough: Novavax's Single-Dose H5N1 Vaccine Proves Effective Against Bird Flu Variants - Stock Titan
BTIG Maintains a Buy Rating on Novavax (NVAX), Sets a $19 PT - MSN
Novavax Inc. Stock Analysis and ForecastFast-track wealth growth - jammulinksnews.com
Novavax (NVAX) Price Target Lowered by B of A Securities | NVAX Stock News - GuruFocus
Novavax (NVAX) Price Target Lowered by BofA to $9 | NVAX Stock N - GuruFocus
Chief Strategist O’Hara On Novavax’s Partnership-Focused Approach - insights.citeline.com
(NVAX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):